Repure Life Sciencee and Industry-Academic Cooperation Foundation of Yonsei University College of Medicine and Gyeongnam Biopharma signed a contract for the joint research and development of 'COVID-19 derived plasma-derived therapeutic antibody'.
This is the first contract signed on May 27, after a joint research agreement aimed at developing a COVID-19 treatment has been completed.
Repure Life Science and Gyeongnam Biopharma will support new drug R&D know-how and manpower through this study. Yonsei University Severance Hospital uses the plasma of the healer of the infectious medicine professor Jun-Yong Choi and the professor of endocrinology and Eunjik Lee, who showed the therapeutic effect, and selects COVID-19 epitopes based on immune proteins in the plasma, and responds to them. It is a policy to develop a therapeutic antibody with high stability and efficacy through securing the CDR region sequence of the antibody, and to discuss the development of a therapeutic agent capable of mass production in the future.
The treatment with plasma of cured teeth was also used in cases of new virus infections such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Ebola virus, and bird flu, and suffered from developing drugs after COVID-19 spread. It is emerging as a response treatment plan.
Professor Jun-Yong Choi's research team had been diagnosed as 'cured' in April after administering plasma treatments for two severe COVID-19 patients aged 67 and 71 who had not improved their condition after treatment with malaria and AIDS.
In the meantime, existing blood plasma products developed at home and abroad have been proceeded in a simple way by separating blood cells and plasma from the blood of a cured person, and this has been raised several times due to stability and efficacy, lack of plasma supply and demand, etc. Unlike most plasma therapeutics development projects, it is developed in a way to find antibodies that are effective for the treatment of COVID-19 in isolated plasma with the latest immunoproteomics method, thus securing efficacy and stability and developing them as therapeutics that can be mass-produced in the future. There is a distinction in this possible point.
In order to develop new drugs using know-how, AI, and big data on new drug development, high therapeutic efficacy is expected with the participation of Repure Life Science in collaboration with the Milner Therapeutics Institute.
An official from Gyeongnam Biopharma said, "If successful derivation of a therapeutic antibody is achieved, it is expected that the shortage of plasma supply will be able to cure thousands and tens of thousands of people." "It can be effectively applied to the production of therapeutic antibodies."